t(8;21) and SON in Blood Cell Proliferation and Differentiation
t(8;21) and SON in Blood Cell Proliferation and Differentiation
批准号:
7580839
负责人:
DONG-ER ZHANG
金额:
$36.97万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2013-11-30
关键词:
AML1-ETO fusion proteinAcute Myelocytic LeukemiaAddressBiological ProcessBlood CellsCell ProliferationCellsChromosomal translocationDNADevelopmentFundingGenesGeneticGeographic LocationsGoalsGranulocyte-Macrophage Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating Factor ReceptorsGrowth FactorHematopoiesisHematopoieticHematopoietic Cell Growth FactorsHumanIL3 geneInterleukin-3Malignant NeoplasmsMutationPopulationProcessProteinsRNA Recognition MotifRUNX1 geneReceptor SignalingReportingRoleSex ChromosomesSignal TransductionSonTestingZinc Fingerscell transformationinsightleukemialeukemogenesispublic health relevancet(821)(q22q22)
中文摘要
描述(由申请人提供):本提案的总体目标是了解白血病发生过程中血细胞转化的机制。染色体易位经常参与白血病的发展过程。在各种易位中,t(8;21)(q22;q22)在8-20%的急性髓性白血病(AML)病例中报告,这取决于人群的遗传背景和地理位置,这使其成为与AML相关的最常见的易位之一。这种易位导致AML 1和ETO基因融合,并产生各种形式的AML 1-ETO融合蛋白。在之前的资助期间,我们发现其他突变,如由于人类性染色体之一丢失或AML 1- ETO的NHR 4锌指结构域缺失或突变导致的造血生长因子信号转导异常,在AML发展中与t(8;21)协同作用。此外,我们确定了一个DNA和RNA结合结构域包含蛋白质称为SON,特异性地与ETO的NHR 4锌指结构域相互作用。在目前的资助期间,我们建议测试的假设,破坏IL-3和/或GM-CSF信号转导是一个主要的额外的突变与t(8;21)白血病发展中的一个人类性染色体的损失,SON是造血细胞的关键因素。具体目标1中提出的研究将确定IL 3和GM-CSF受体信号转导在t(8;21)相关白血病发展中的作用。具体目标2中提出的研究将描述SON在AML 1-ETO参与的白血病发生中的作用。具体目标3中提出的研究将分析SON在造血中的生物学功能。这些研究将解决有关造血和白血病发生的重要问题,这可能为白血病和其他癌症的治疗提供有价值的见解。公共卫生相关性:t(8;21)是AML中常见的染色体易位。我们拟研究生长因子IL 3、GM-CSF和SON蛋白的异常信号传导如何参与t(8;21)相关的白血病发生,以及SON如何参与造血。这些研究将解决有关造血和白血病发生的重要问题,这可能为白血病和其他癌症的治疗提供有价值的见解。
英文摘要
DESCRIPTION (provided by applicant): The overall goal of this proposal is to understand the mechanism of blood cell transformation during leukemogenesis. Chromosomal translocations are frequently involved in the process of leukemia development. Among various translocations, t(8;21)(q22;q22) is reported in 8-20% cases of acute myeloid leukemia (AML) depending on the genetic background and geographic locations of the population, which makes it one of the most common translocations associated with AML. This translocation leads to the fusion of the AML1 and ETO genes and generates various forms of AML1-ETO fusion proteins. In the previous funding period, we discovered that additional mutations, such as abnormal hematopoietic growth factor signal transduction due to loss of one of the human sex chromosomes or deletion or mutation of the NHR4 zinc finger domain of AML1- ETO, cooperate with t(8;21) in AML development. Furthermore, we identified a DNA and RNA binding domain containing protein called SON that specifically interacts with the NHR4 zinc finger domain of ETO. In the current funding period, we propose to test the hypotheses that disrupting IL-3 and/or GM-CSF signal transduction is a major additional mutation associated with loss of one human sex chromosome in t(8;21) leukemia development and that SON is a critical factor in hematopoietic cells. The studies proposed in Specific Aim 1 will define the role of IL3 and GM-CSF receptor signal transduction in the development of t(8;21) related leukemia. The studies proposed in Specific Aim 2 will characterize the role of SON in AML1-ETO involved leukemogenesis. The studies proposed in Specific Aim 3 will analyze the biological function of SON in hematopoiesis. These studies will address important questions about hematopoiesis and leukemogenesis, which may provide valuable insight into the treatment of leukemia and other cancers. PUBLIC HEALTH RELEVANCE: t(8;21) is a common chromosomal translocation in AML. We propose to study how abnormal signaling of growth factors IL3 and GM-CSF and a protein SON are involved in t(8;21) associated leukemogenesis and how SON is involved in hematopoiesis. These studies will address important questions about hematopoiesis and leukemogenesis, which may provide valuable insight into the treatment of leukemia and other cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
USP18 in Cancer Development
-
批准号:10596566
-
项目类别:
-
资助金额:$37.09万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
USP18 in Cancer Development
-
批准号:9886213
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
USP18 in Cancer Development
-
批准号:10377534
-
项目类别:
-
资助金额:$37.09万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
USP18 in Cancer Development
-
批准号:10132268
-
项目类别:
-
资助金额:$37.82万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
CSF2 receptor mediated actions in t(8;21) leukemia
-
批准号:9014529
-
项目类别:
-
资助金额:$34.49万
-
财政年份:2015
-
负责人:DONG-ER ZHANG
-
依托单位:
CSF2 receptor mediated actions in t(8;21) leukemia
-
批准号:8842430
-
项目类别:
-
资助金额:$34.59万
-
财政年份:2015
-
负责人:DONG-ER ZHANG
-
依托单位:
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
-
批准号:10400021
-
项目类别:
-
资助金额:$62.03万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and protein ISGylation in Cancer
-
批准号:8616739
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and protein ISGylation in Cancer
-
批准号:8535417
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
-
批准号:9922899
-
项目类别:
-
资助金额:$64.18万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and Protein ISGylation in Cancer
-
批准号:10116297
-
项目类别:
-
资助金额:$41.43万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and Protein ISGylation in Cancer
-
批准号:10590733
-
项目类别:
-
资助金额:$40.51万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and protein ISGylation in Cancer
-
批准号:9002027
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and Protein ISGylation in Cancer
-
批准号:10360673
-
项目类别:
-
资助金额:$40.78万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
International RUNX Workshop
-
批准号:8129107
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2011
-
负责人:DONG-ER ZHANG
-
依托单位:
SEARCH AML1-ETO INTERACTING PROTEIN
-
批准号:8171272
-
项目类别:
-
资助金额:$0.24万
-
财政年份:2010
-
负责人:DONG-ER ZHANG
-
依托单位:
UBP43 in Hematopoiesis
-
批准号:7919940
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
SEARCH AML1-ETO INTERACTING PROTEIN
-
批准号:7723659
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
UBP43 in Hematopoiesis
-
批准号:8318588
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
UBP43 in Hematopoiesis
-
批准号:7687335
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
海外基金